Cargando…

Opioid agonist treatment take-home doses (‘carries’): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA?

Opioid agonist treatment (OAT) is the primary intervention for opioid use disorder (OUD) in Canada and the USA. Yet, a number of barriers contribute to sub-optimal treatment uptake and retention, including daily-supervised medication administration. Thus, clients are eventually granted access to tak...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russell, Cayley, Lange, Shannon, Kouyoumdjian, Fiona, Butler, Amanda, Ali, Farihah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363267/ https://www.ncbi.nlm.nih.gov/pubmed/35948961 http://dx.doi.org/10.1186/s12954-022-00671-z

Ejemplares similares

Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey
por: Kouyoumdjian, Fiona G., et al.
Publicado: (2018)

Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015–2018: a repeated cross-sectional analysis
por: Bodkin, Claire, et al.
Publicado: (2021)

Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada
por: Russell, Cayley, et al.
Publicado: (2022)

Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study
por: Russell, Cayley, et al.
Publicado: (2022)

The impact of methamphetamine use on medications for opioid use disorder (MOUD) treatment retention: a scoping review
por: Russell, Cayley, et al.
Publicado: (2023)

Rescue Analgesia for Opioid-Dependent Individuals on Opioid Agonist Treatment during Hospitalization: Adherence to Guideline Treatment
por: Arnet, Isabelle, et al.
Publicado: (2023)

Trends in Rates of Opioid Agonist Treatment and Opioid-Related Deaths for Youths in Ontario, Canada, 2013-2021
por: Rosic, Tea, et al.
Publicado: (2023)

A qualitative examination of substance use service needs among people who use drugs (PWUD) with treatment and service experience in Ontario, Canada
por: Russell, Cayley, et al.
Publicado: (2021)

Assessing service and treatment needs and barriers of youth who use illicit and non-medical prescription drugs in Northern Ontario, Canada
por: Russell, Cayley, et al.
Publicado: (2019)

Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans
por: Eydt, Erin, et al.
Publicado: (2021)

Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Alcohol use in opioid agonist treatment
por: Nolan, Seonaid, et al.
Publicado: (2016)

Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
por: Regenstreif, Lori, et al.
Publicado: (2022)

Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework
por: Tahsin, Farah, et al.
Publicado: (2022)

Opioid Dependence Treatment and Guidelines
por: Nicholls, Lance, et al.
Publicado: (2010)

The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data
por: Imtiaz, Sameer, et al.
Publicado: (2021)

Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: A national qualitative assessment in Canada
por: Ali, Farihah, et al.
Publicado: (2021)

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
por: Palis, Heather, et al.
Publicado: (2021)

Interim opioid agonist treatment for opioid addiction: a systematic review
por: Samsó Jofra, Laura, et al.
Publicado: (2022)

Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
por: Morin, Kristen A., et al.
Publicado: (2019)

Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Characterizing opioid agonist therapy uptake and factors associated with treatment retention among people with HIV in British Columbia, Canada
por: Yazdani, Kiana, et al.
Publicado: (2023)

Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis
por: Kitchen, Sophie A., et al.
Publicado: (2022)

The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada
por: Franklyn, Alexandra M., et al.
Publicado: (2017)

Expanding HAART Treatment to All Currently Eligible Individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada
por: Lima, Viviane D., et al.
Publicado: (2010)

Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes
por: Day, Nathaniel, et al.
Publicado: (2022)

Evidence of Increased Age and Sex Standardized Death Rates Among Individuals Who Accessed Opioid Agonist Treatment Before the Era of Synthetic Opioids in Ontario, Canada
por: Morin, Kristen A, et al.
Publicado: (2021)

Correction to: Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
por: Morin, Kristen A., et al.
Publicado: (2019)

Evaluating the effectiveness of concurrent opioid agonist treatment and physician-based mental health services for patients with mental disorders in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2020)

Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study
por: Larney, Sarah, et al.
Publicado: (2018)

Guidance on take-home naloxone distribution and use by community overdose responders in Canada
por: Ferguson, Max, et al.
Publicado: (2023)

Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2023)

Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review
por: Pijl, Em M., et al.
Publicado: (2022)

Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review
por: Moustaqim-Barrette, Amina, et al.
Publicado: (2021)

Changing Pattern of Opioid Users Attending an Opioid Agonist Treatment Clinic in North India
por: Bhat, Fazle R., et al.
Publicado: (2022)

What is the benefit of inconsistent opioid agonist treatment in patients with prescription opioid use disorder?
por: Weiss, R., et al.
Publicado: (2023)

Take-home Naloxone at Opioid Treatment Programs: A Lifesaver
por: Katzman, Joanna G., et al.
Publicado: (2022)

Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study
por: Morin, Kristen A, et al.
Publicado: (2022)

Consensus recommendations for opioid agonist treatment following the introduction of emergency clinical guidelines in Ireland during the COVID-19 pandemic: A national Delphi study
por: Durand, Louise, et al.
Publicado: (2022)

Corrigendum to “Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study” [Journal of Substance Abuse Treatment 129 (2021) 108374]
por: Russell, Cayley, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cc96rantod0q48g7da89qt99f1